CIBC Asset Management Inc raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,684 shares of the biopharmaceutical company’s stock after acquiring an additional 264 shares during the quarter. CIBC Asset Management Inc’s holdings in Regeneron Pharmaceuticals were worth $5,224,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. FMR LLC increased its position in Regeneron Pharmaceuticals by 6.3% in the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after buying an additional 416,192 shares in the last quarter. BlackRock Inc. increased its position in Regeneron Pharmaceuticals by 0.7% in the second quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock worth $3,039,305,000 after buying an additional 41,406 shares in the last quarter. Vanguard Group Inc. increased its position in Regeneron Pharmaceuticals by 2.9% in the second quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock worth $2,588,533,000 after buying an additional 148,962 shares in the last quarter. Artisan Partners Limited Partnership increased its position in Regeneron Pharmaceuticals by 1.5% in the second quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock worth $963,852,000 after buying an additional 29,252 shares in the last quarter. Finally, Polen Capital Management LLC increased its position in Regeneron Pharmaceuticals by 7.3% in the second quarter. Polen Capital Management LLC now owns 1,586,320 shares of the biopharmaceutical company’s stock worth $779,105,000 after buying an additional 108,413 shares in the last quarter. 67.80% of the stock is currently owned by institutional investors.

Several analysts recently issued reports on the company. Royal Bank Of Canada reiterated a “sector perform” rating and set a $425.00 target price (down previously from $473.00) on shares of Regeneron Pharmaceuticals in a research report on Thursday, November 9th. J P Morgan Chase & Co restated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Citigroup Inc. restated a “buy” rating and set a $480.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, November 9th. Leerink Swann restated an “outperform” rating and set a $580.00 price target (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Finally, Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 price target for the company in a report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $481.49.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded down $8.82 during midday trading on Wednesday, reaching $384.80. The company’s stock had a trading volume of 1,109,100 shares, compared to its average volume of 903,660. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. The company has a market cap of $42,176.78, a price-to-earnings ratio of 34.08, a PEG ratio of 1.55 and a beta of 1.56. Regeneron Pharmaceuticals, Inc. has a 1-year low of $340.09 and a 1-year high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. During the same period in the previous year, the company posted $3.13 EPS. Regeneron Pharmaceuticals’s revenue was up 23.0% on a year-over-year basis. equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/15/cibc-asset-management-inc-purchases-264-shares-of-regeneron-pharmaceuticals-inc-regn.html.

In other news, Chairman P Roy Vagelos sold 1,305 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $470.00, for a total value of $613,350.00. Following the transaction, the chairman now directly owns 329,543 shares in the company, valued at approximately $154,885,210. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Sanofi purchased 166,415 shares of the business’s stock in a transaction dated Thursday, August 24th. The stock was bought at an average price of $480.93 per share, for a total transaction of $80,033,965.95. The disclosure for this purchase can be found here. Insiders sold a total of 77,956 shares of company stock worth $36,898,788 over the last quarter. Company insiders own 10.80% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.